30th October 2024 - A Tribute to Professor Kristian Berg Innovative Approaches for Cancer Targeting
On the occasion of Professor Kristian Berg’s retirement, the Institute for Cancer Research and Oslo Cancer Cluster are pleased to announce the symposium “Innovative Approaches for Cancer Targeting” 30th October 2024.
We are proud to present an extraordinary program in the intersection of Reactive Oxygen Species, Photomedicine, Endocytosis and Antibody Drug Conjugates (ADCs). The program includes national and international speakers and has high focus on innovation and clinical implementation of research findings.
Links:
Speakers bio (PDF)
Program (PDF) (updated Oct 28)
Kristian Berg has through his 40 years as an innovative researcher obtained high international recognition for his contributions in the field of photodynamic therapy. He has been outstanding in translating and implementing his research into clinical use and his contributions has been fundamental for the establishment of 2 pharmaceutical companies on the Oslo Stock exchange. During the last years Berg has been admitted to the Rab5 project developing novel biomarkers for antibody drug conjugates (ADCs), and is the co-founder of Rab Diagnostics, a recently established spin-out company based on this project.
Berg has contributed to high impact scientific research on all continents; has been fundamental in national and international education of the next generation photobiologist, and has contributed in the design of clinical trials. At the Institute for Cancer Research, Berg has been the leader of the PCI group for 20 years and Head of Department of Radiation Biology until last summer. His scientific track record includes 250 publications and 11 patents. He has been engaged in numerous boards and has received several awards including the ESP Award for Excellence in Photobiological Research (2013) the European Commission’s Innovation Radar Prize (2019) and the IUPB Finsen medal (2024) for outstanding contributions to the photosciences.
More links:
Photochemical internalisation (PCI) research group, headed by Kristian Berg